Skip to main content
SpringerLink
Log in

Genetics of Hereditary Breast Cancer

  • Chapter
  • First Online:
Book cover Principles of Clinical Cancer Genetics

  • 1353 Accesses

Abstract

The identification and clinical management of patients at inherited risk for breast cancer has become an integral part of the practice of preventative medicine and oncology. Although only about 5–10% of all cases of breast cancer are attributable to a highly penetrant cancer predisposition gene, individuals who carry a cancer susceptibility gene mutation have a significantly higher risk of developing breast cancer, as well as other cancers, over their lifetime compared to the general population. The ability to distinguish those individuals at high risk allows physicians and other health-care providers to intervene with appropriate counseling and education, surveillance, and prevention – with the overall goal of improved survival for these individuals. Recently, a number of germline alleles have been identified that have a modest impact on the risk of breast cancer [1] but there remain only a handful of genes in which a mutation substantially elevates the risk of breast cancer. These include BRCA1, BRCA2, TP53, PTEN, and CDH1. This chapter will provide an overview of the clinical features, cancer risks, causative genes, and medical management for the most clearly described hereditary breast cancer syndromes with particular attention to the most frequently encountered hereditary breast and ovarian cancer syndrome (HBOC) due to an underlying mutation in BRCA1 or BRCA2. The surgical management of HBOC will be discussed in Chap. 4.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Easton DF, Pooley KA, Dunning AM et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148):1087–1093

    Article  PubMed  CAS  Google Scholar 

  2. Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62(3):676–689

    Article  PubMed  CAS  Google Scholar 

  3. Gudmundsdottir K, Ashworth A (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25(43):5864–5874

    Article  PubMed  CAS  Google Scholar 

  4. Chappuis PO, Nethercot V, Foulkes WD (2000) Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18(4):287–295

    Article  PubMed  CAS  Google Scholar 

  5. Phillips KA, Andrulis IL, Goodwin PJ (1999) Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? J Clin Oncol 17(11):3653–3663

    PubMed  CAS  Google Scholar 

  6. Bane AL, Beck JC, Bleiweiss I et al (2007) BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 31(1):121–128

    Article  PubMed  Google Scholar 

  7. Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25(43):5846–5853

    Article  PubMed  CAS  Google Scholar 

  8. Eisinger F, Nogues C, Birnbaum D, Jacquemier J, Sobol H (1998) BRCA1 and medullary breast cancer. JAMA 280(14):1227–1228

    Article  PubMed  CAS  Google Scholar 

  9. Hosey AM, Gorski JJ, Murray MM et al (2007) Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 99(22):1683–1694

    Article  PubMed  CAS  Google Scholar 

  10. Lakhani SR, Reis-Filho JS, Fulford L et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11(14):5175–5180

    Article  PubMed  CAS  Google Scholar 

  11. Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71

    Article  PubMed  CAS  Google Scholar 

  12. Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792

    Article  PubMed  CAS  Google Scholar 

  13. Wooster R, Neuhausen SL, Mangion J et al (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265(5181):2088–2090

    Article  PubMed  CAS  Google Scholar 

  14. Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12):1379–1388

    Article  PubMed  CAS  Google Scholar 

  15. Nagy R, Sweet K, Eng C (2004) Highly penetrant hereditary cancer syndromes. Oncogene 23(38):6445–6470

    Article  PubMed  CAS  Google Scholar 

  16. Easton DF, Deffenbaugh AM, Pruss D et al (2007) A systematic genetic assessment of 1, 433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81(5):873–883

    Article  PubMed  CAS  Google Scholar 

  17. Xia B, Sheng Q, Nakanishi K et al (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22(6):719–729

    Article  PubMed  CAS  Google Scholar 

  18. Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20):1401–1408

    Article  PubMed  CAS  Google Scholar 

  19. Kauff ND, Perez-Segura P, Robson ME et al (2002) Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 39(8):611–614

    Article  PubMed  CAS  Google Scholar 

  20. Thorlacius S, Olafsdottir G, Tryggvadottir L et al (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13(1):117–119

    Article  PubMed  CAS  Google Scholar 

  21. Unger MA, Nathanson KL, Calzone K et al (2000) Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 67(4):841–850

    Article  PubMed  CAS  Google Scholar 

  22. Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130

    Article  PubMed  CAS  Google Scholar 

  23. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646

    Article  PubMed  CAS  Google Scholar 

  24. Risch HA, McLaughlin JR, Cole DE et al (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68(3):700–710

    Article  PubMed  CAS  Google Scholar 

  25. Thompson D, Easton D (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68(2):410–419

    Article  PubMed  CAS  Google Scholar 

  26. Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616–1622

    Article  PubMed  Google Scholar 

  27. Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609–1615

    Article  PubMed  Google Scholar 

  28. Easton D, Thompson D, McGuffog L et al (1999) Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91(15):1310–1316

    Article  Google Scholar 

  29. Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22(4):735–742

    Article  PubMed  CAS  Google Scholar 

  30. Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365

    Article  PubMed  CAS  Google Scholar 

  31. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ et al (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42(9):711–719

    Article  PubMed  Google Scholar 

  32. Boyd J, Sonoda Y, Federici MG et al (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283(17):2260–2265

    Article  PubMed  CAS  Google Scholar 

  33. Lakhani SR, Manek S, Penault-Llorca F et al (2004) Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 10(7):2473–2481

    Article  PubMed  CAS  Google Scholar 

  34. Levine DA, Argenta PA, Yee CJ et al (2003) Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21(22):4222–4227

    Article  PubMed  CAS  Google Scholar 

  35. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97(9):2187–2195

    Article  PubMed  CAS  Google Scholar 

  36. Smith P, McGuffog L, Easton DF et al (2006) A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45(7):646–655

    Article  PubMed  CAS  Google Scholar 

  37. Hunter DJ, Kraft P, Jacobs KB et al (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39(7):870–874

    Article  PubMed  CAS  Google Scholar 

  38. Stacey SN, Manolescu A, Sulem P et al (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39(7):865–869

    Article  PubMed  CAS  Google Scholar 

  39. Frank B, Wiestler M, Kropp S et al (2008) Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. J Natl Cancer Inst 100(6):437–442

    Article  PubMed  CAS  Google Scholar 

  40. Gold B, Kirchhoff T, Stefanov S et al (2008) Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A 105(11):4340–4345

    Article  PubMed  CAS  Google Scholar 

  41. Nevanlinna H, Bartek J (2006) The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25(43):5912–5919

    Article  PubMed  CAS  Google Scholar 

  42. Erkko H, Xia B, Nikkila J et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446(7133):316–319

    Article  PubMed  CAS  Google Scholar 

  43. Foulkes WD, Ghadirian P, Akbari MR et al (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 9(6):R83

    Article  PubMed  CAS  Google Scholar 

  44. Liebens FP, Carly B, Pastijn A, Rozenberg S (2007) Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 43(2):238–257

    Article  PubMed  CAS  Google Scholar 

  45. Metcalfe K, Lynch HT, Ghadirian P et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22(12):2328–2335

    Article  PubMed  CAS  Google Scholar 

  46. Pierce LJ, Levin AM, Rebbeck TR et al (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24(16):2437–2443

    Article  PubMed  Google Scholar 

  47. Moller P, Evans DG, Reis MM et al (2007) Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer 121(5):1017–1020

    Article  PubMed  CAS  Google Scholar 

  48. Rennert G, Bisland-Naggan S, Barnett-Griness O et al (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(2):115–123

    Article  PubMed  CAS  Google Scholar 

  49. Foulkes WD, Metcalfe K, Hanna W et al (2003) Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 98(8):1569–1577

    Article  PubMed  Google Scholar 

  50. Robson M, Svahn T, McCormick B et al (2005) Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 103(1):44–51

    Article  PubMed  Google Scholar 

  51. Rodriguez-Pinilla SM, Sarrio D, Honrado E et al (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12(5):1533–1539

    Article  PubMed  CAS  Google Scholar 

  52. Moynahan ME, Cui TY, Jasin M (2001) Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 61(12):4842–4850

    PubMed  CAS  Google Scholar 

  53. Tutt A, Bertwistle D, Valentine J et al (2001) Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 20(17):4704–4716

    Article  PubMed  CAS  Google Scholar 

  54. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275(31):23899–23903

    Article  PubMed  CAS  Google Scholar 

  55. Howlett NG, Taniguchi T, Olson S et al (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297(5581):606–609

    Article  PubMed  CAS  Google Scholar 

  56. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96(22):1659–1668

    Article  PubMed  CAS  Google Scholar 

  57. Byrski T, Gronwald J, Huzarski T et al (2008) Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 108(2):289–296

    Article  PubMed  CAS  Google Scholar 

  58. Zhou C, Smith JL, Liu J (2003) Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 22(16):2396–2404

    Article  PubMed  CAS  Google Scholar 

  59. Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108(2):171–182

    Article  PubMed  CAS  Google Scholar 

  60. Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26(22):3785–3790

    Article  PubMed  CAS  Google Scholar 

  61. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921

    Article  PubMed  CAS  Google Scholar 

  62. Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913–917

    Article  PubMed  CAS  Google Scholar 

  63. McCabe N, Turner NC, Lord CJ et al (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66(16):8109–8115

    Article  PubMed  CAS  Google Scholar 

  64. McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A (2005) BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 4(9):934–936

    Article  PubMed  CAS  Google Scholar 

  65. Hay T, Jenkins H, Sansom OJ, Martin NM, Smith GC, Clarke AR (2005) Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res 65(22):10145–10148

    Article  PubMed  CAS  Google Scholar 

  66. Rottenberg S, Nygren AO, Pajic M et al (2007) Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 104(29):12117–12122

    Article  PubMed  CAS  Google Scholar 

  67. Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134

    Article  PubMed  CAS  Google Scholar 

  68. Johnson N, Fletcher O, Palles C et al (2007) Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 16(9):1051–1057

    Article  PubMed  CAS  Google Scholar 

  69. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100(14):8418–8423

    Article  PubMed  CAS  Google Scholar 

  70. Turner NC, Reis-Filho JS, Russell AM et al (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26(14):2126–2132

    Article  PubMed  CAS  Google Scholar 

  71. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL (2005) BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 91(2):179–186

    Article  PubMed  CAS  Google Scholar 

  72. Abd El-Rehim DM, Ball G, Pinder SE et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350

    Article  PubMed  CAS  Google Scholar 

  73. Richardson AL, Wang ZC, De Nicolo A et al (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9(2):121–132

    Article  PubMed  CAS  Google Scholar 

  74. Hartmann LC, Sellers TA, Schaid DJ et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93(21):1633–1637

    Article  PubMed  CAS  Google Scholar 

  75. Sardanelli F, Podo F, D’Agnolo G et al (2007) Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 242(3):698–715

    Article  PubMed  Google Scholar 

  76. Kriege M, Brekelmans CT, Boetes C et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437

    Article  PubMed  CAS  Google Scholar 

  77. Warner E, Plewes DB, Hill KA et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292(11):1317–1325

    Article  PubMed  CAS  Google Scholar 

  78. Stoutjesdijk MJ, Boetes C, Jager GJ et al (2001) Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 93(14):1095–1102

    Article  PubMed  CAS  Google Scholar 

  79. NCCN (2009) NCCN Clinical Practice Guidelines in oncology: high-risk assesment: breast and ovarian. V.1.2009

    Google Scholar 

  80. Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055–1062

    Article  PubMed  Google Scholar 

  81. Meijers-Heijboer H, van Geel B, van Putten WL et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345(3):159–164

    Article  PubMed  CAS  Google Scholar 

  82. Piver MS, Jishi MF, Tsukada Y, Nava G (1993) Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71(9):2751–2755

    Article  PubMed  CAS  Google Scholar 

  83. Burke W, Daly M, Garber J et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277(12):997–1003

    Article  PubMed  CAS  Google Scholar 

  84. Modan B, Hartge P, Hirsh-Yechezkel G et al (2001) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345(4):235–240

    Article  PubMed  CAS  Google Scholar 

  85. Narod SA, Risch H, Moslehi R et al (1998) Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339(7):424–428

    Article  PubMed  CAS  Google Scholar 

  86. Narod SA, Dube MP, Klijn J et al (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94(23):1773–1779

    Article  PubMed  CAS  Google Scholar 

  87. Milne RL, Knight JA, John EM et al (2005) Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 14(2):350–356

    Article  PubMed  CAS  Google Scholar 

  88. King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286(18):2251–2256

    Article  PubMed  CAS  Google Scholar 

  89. Narod SA, Brunet JS, Ghadirian P et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356(9245):1876–1881

    Article  PubMed  CAS  Google Scholar 

  90. Gronwald J, Tung N, Foulkes WD et al (2006) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118(9):2281–2284

    Article  PubMed  CAS  Google Scholar 

  91. Sidransky D, Tokino T, Helzlsouer K et al (1992) Inherited p53 gene mutations in breast cancer. Cancer Res 52(10):2984–2986

    PubMed  CAS  Google Scholar 

  92. Li FP, Fraumeni JF Jr, Mulvihill JJ et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48(18):5358–5362

    PubMed  CAS  Google Scholar 

  93. Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10(2):83–87

    PubMed  CAS  Google Scholar 

  94. Hartley AL, Birch JM, Marsden HB, Harris M (1987) Malignant melanoma in families of children with osteosarcoma, chondrosarcoma, and adrenal cortical carcinoma. J Med Genet 24(11):664–668

    Article  PubMed  CAS  Google Scholar 

  95. Jay M, McCartney AC (1993) Familial malignant melanoma of the uvea and p53: a Victorian detective story. Surv Ophthalmol 37(6):457–462

    Article  PubMed  CAS  Google Scholar 

  96. Birch JM, Alston RD, McNally RJ et al (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20(34):4621–4628

    Article  PubMed  CAS  Google Scholar 

  97. Hwang SJ, Lozano G, Amos CI, Strong LC (2003) Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 72(4):975–983

    Article  PubMed  CAS  Google Scholar 

  98. Chompret A, Brugieres L, Ronsin M et al (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82(12):1932–1937

    Article  PubMed  CAS  Google Scholar 

  99. Le Bihan C, Bonaiti-Pellie C (1994) A method for estimating cancer risk in p53 mutation carriers. Cancer Detect Prev 18(3):171–178

    PubMed  Google Scholar 

  100. Birch JM, Hartley AL, Tricker KJ et al (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54(5):1298–1304

    PubMed  CAS  Google Scholar 

  101. Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surv 25:101–124

    PubMed  CAS  Google Scholar 

  102. Gonzalez KD, Noltner KA, Buzin CH et al (2009) Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations. J Clin Oncol 27(8):1250–1256

    Article  PubMed  CAS  Google Scholar 

  103. Starink TM, van der Veen JP, Arwert F et al (1986) The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 29(3):222–233

    Article  PubMed  CAS  Google Scholar 

  104. Brownstein MH, Wolf M, Bikowski JB (1978) Cowden’s disease: a cutaneous marker of breast cancer. Cancer 41(6):2393–2398

    Article  PubMed  CAS  Google Scholar 

  105. Eng C (2003) PTEN: one gene, many syndromes. Hum Mutat 22(3):183–198

    Article  PubMed  CAS  Google Scholar 

  106. Fackenthal JD, Marsh DJ, Richardson AL et al (2001) Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 38(3):159–164

    Article  PubMed  CAS  Google Scholar 

  107. Li J, Yen C, Liaw D et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308):1943–1947

    Article  PubMed  CAS  Google Scholar 

  108. Eng C (2002) Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carcinogenesis. Ann N Y Acad Sci 968:213–221

    Article  PubMed  CAS  Google Scholar 

  109. Marsh DJ, Kum JB, Lunetta KL et al (1999) PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 8(8):1461–1472

    Article  PubMed  CAS  Google Scholar 

  110. Saslow D, Castle PE, Cox JT et al (2007) American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57(1):7–28

    Article  PubMed  Google Scholar 

  111. Charlton A, Blair V, Shaw D, Parry S, Guilford P, Martin IG (2004) Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 53(6):814–820

    Article  PubMed  CAS  Google Scholar 

  112. Guilford PJ, Hopkins JB, Grady WM et al (1999) E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 14(3):249–255

    Article  PubMed  CAS  Google Scholar 

  113. Pharoah PD, Guilford P, Caldas C (2001) Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121(6):1348–1353

    Article  PubMed  CAS  Google Scholar 

  114. Graziano F, Humar B, Guilford P (2003) The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol 14(12):1705–1713

    Article  PubMed  CAS  Google Scholar 

  115. Brooks-Wilson AR, Kaurah P, Suriano G et al (2004) Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 41(7):508–517

    Article  PubMed  CAS  Google Scholar 

  116. Gene tests. GeneTests 2009; available at www.ncbi.nlm.nih.gov/sites/GeneTests/?db = GeneTests

Download references

Author information

Authors and Affiliations

  1. Breast and Ovarian Cancer Genetics and Risk Assessment Clinic, Massachusetts General Hospital, Boston, MA, USA

    Paula D. Ryan

Authors
  1. Paula D. Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paula D. Ryan .

Editor information

Editors and Affiliations

  1. Cancer Center and Gastrointestinal Unit, Harvard Medical School, Massachusetts General Hospital, Boston, 02114, USA

    Daniel C. Chung

  2. Cancer Center, Harvard Medical School and, Massachusetts General Hospital, Boston, 02114, USA

    Daniel A. Haber

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ryan, P.D. (2010). Genetics of Hereditary Breast Cancer. In: Chung, D., Haber, D. (eds) Principles of Clinical Cancer Genetics. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-93846-2_3

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-93846-2_3

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-93844-8

  • Online ISBN: 978-0-387-93846-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation